ProTriTACs have the potential for additional tumor specificity and enhanced safety profiles due to limited interaction with their molecular targets in healthy tissue, which enables targeting tumor-associated antigens that may be more broadly expressed. Harpoon has nominated its first ProTriTAC product candidate, HPN601, which targets epithelial cell adhesion molecule (EpCAM), and is applicable to a wide array of solid tumors.
HPN328 targets Delta-like canonical Notch ligand 3 (DL元) for the treatment of small cell lung cancer (SCLC) and other DL元-expressing tumors.
Harpoon remains on track to initiate a Phase 1/2 clinical trial for HPN328 in the fourth quarter, which will be our fourth TriTAC in clinical development.Third Quarter 2020 Business Highlights and Other Recent Developments “Additionally, we expect to advance our HPN424, HPN536, and HPN217 clinical programs in the fourth quarter and present preclinical data at SITC for our first ProTriTAC development program, HPN601, for the treatment of solid tumor malignancies.” “We continue to be excited by the advancement of our novel TriTAC pipeline, and are planning for our fourth program, HPN328, to enter the clinic this year for the treatment of DL元-expressing tumors including small cell lung cancer,” said Gerald McMahon, Ph.D., President and Chief Executive Officer of Harpoon Therapeutics. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended Septemand provided a corporate update. 04, 2020 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc.